<DOC>
	<DOC>NCT02676531</DOC>
	<brief_summary>This study is to evaluate the effects of Walking Meditation on vascular function in breast cancer patients receiving Anthracyclines chemotherapy</brief_summary>
	<brief_title>Walking Meditation Exercise in Breast Cancer Patients</brief_title>
	<detailed_description>Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound "Budd" and "Dha" and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1. The inclusion criteria included stage 12 of Breast cancer patients after an operation with or without Hormone Receptor Positive and HER2 Positive. 2. All participants will be planned to use Anthracyclines chemotherapy in next 1 month by oncologist. 3. All participants did not participate in any exercise training in the past 6 months 4. All participants are free from acute or chronic renal failure, Heart Failure, Myasthenia gravis, pregnancy and history of smoke. 1. Participants will be excluded if they dropped out or completed less than 80% of the training schedule.</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Walking Meditation</keyword>
	<keyword>Vascular Function</keyword>
	<keyword>Flow-mediated dilatation</keyword>
	<keyword>Breast Cancer Patients</keyword>
	<keyword>Anthracyclines Chemotherapy</keyword>
</DOC>